Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
about
Elevated PRC1 in gastric carcinoma exerts oncogenic function and is targeted by piperlongumine in a p53-dependent manner.Understanding cell cycle and cell death regulation provides novel weapons against human diseases.Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.Overaccumulation of p53-mediated autophagy protects against betulinic acid-induced apoptotic cell death in colorectal cancer cells.Mutant p53-Nrf2 axis regulates the proteasome machinery in cancerTargeting mutant p53 for cancer therapy.PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors.PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation.Defining key concepts of intestinal and epithelial cancer biology through the use of mouse models.Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1.A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts.Targeting the DNA Damage Response in OSCC with TP53 Mutations.New aspects of antiproliferative activity of 4-hydroxybenzyl isothiocyanate, a natural H2S-donor.Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells.Genomic profiles of primary and metastatic esophageal adenocarcinoma identified via digital sorting of pure cell populations: results from a case report
P2860
Q33844651-3FE83901-2D02-44CC-893A-B2A54382F7C5Q39218376-0C40D680-5D0D-48B6-9BA4-133E3309B84AQ39229004-872D17F3-7B93-482C-A748-524044D83EE5Q41911815-C567E104-59D9-4793-A6F2-79F88E85F9C0Q42325001-C00DC10B-16B5-40FA-AAA9-7D2481F12159Q42433820-5EEE72CC-BCBD-4993-9DB6-D713964B123AQ47274927-3E766AAB-2D70-4993-A4A7-C25106C98A6AQ47721091-62EA372D-DEAF-42B6-80C8-0F940C9C3796Q48507317-F694CC1C-0296-4D6A-B6DE-9321E50E2252Q49579860-DED454F4-B9F0-4EC3-8908-363D628E36D4Q49952370-E9A3D9E3-429C-4F67-97AC-DD464E110DFBQ52722381-5D192D8D-9049-42C7-A715-672D4E9C1D03Q52729908-5611396A-0B7C-4851-A835-39D9257C87F9Q55039774-E2CFFD2A-F870-4803-83AA-9F788D695DC0Q55281959-464F82AB-28C6-43BA-BFDC-7711BAF55079Q58748552-73030A39-15C3-458B-843F-A75E193E28EC
P2860
Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Targeting of Mutant p53 and th ...... y for Efficient Cancer Therapy
@ast
Targeting of Mutant p53 and th ...... y for Efficient Cancer Therapy
@en
Targeting of Mutant p53 and th ...... y for Efficient Cancer Therapy
@nl
type
label
Targeting of Mutant p53 and th ...... y for Efficient Cancer Therapy
@ast
Targeting of Mutant p53 and th ...... y for Efficient Cancer Therapy
@en
Targeting of Mutant p53 and th ...... y for Efficient Cancer Therapy
@nl
prefLabel
Targeting of Mutant p53 and th ...... y for Efficient Cancer Therapy
@ast
Targeting of Mutant p53 and th ...... y for Efficient Cancer Therapy
@en
Targeting of Mutant p53 and th ...... y for Efficient Cancer Therapy
@nl
P2093
P2860
P3181
P356
P1476
Targeting of Mutant p53 and th ...... y for Efficient Cancer Therapy
@en
P2093
Lars Abrahmsen
Meiqiongzi Zhang
Qiang Zhang
Vladimir J N Bykov
P2860
P3181
P356
10.3389/FONC.2016.00021
P407
P577
2016-01-01T00:00:00Z